Systemic lupus erythematosus (SLE) is an autoimmune disease that can’t be cured, and patients have long relied on steroids and broad‑acting immunosuppressants that cause serious side effects. A new biologic, anifrolumab, is showing promise in a late‑stage Phase III trial run by AstraZeneca. In Asian adults with moderate‑to‑severe SLE, the drug significantly lowered disease activity and allowed patients to cut their oral steroid doses compared with a placebo. AstraZeneca says the trial results open the door to a much‑needed treatment option for China, which bears the world’s heaviest lupus burden – roughly one million patients out of a global total of 3.4 million. The company is now pushing the drug through China’s registration process. While other Chinese firms have introduced biologics such as belimumab and telitacicept, anifrolumab could be the first to offer a steroid‑sparing, targeted therapy for a large segment of Chinese patients. Experts warn that despite improved 10‑year survival rates, long‑term organ damage and steroid toxicity still threaten patients after two decades, making innovative drugs like anifrolumab a potential turning point in lupus care.
Read more